What it is
A heptapeptide analogue of a fragment of ACTH, developed in Russia where it is a registered medicine. It is not licensed in the UK, EU or US.
How it is thought to work
Reported to increase BDNF and NGF expression and to influence monoamine systems, without the hormonal effects of full-length ACTH.
What the studies found
-
Registered in Russia for stroke and cognitive indications
Russian clinical studies reported benefit in ischaemic stroke and cognitive disorders, supporting registration there.
-
Neurotrophic effects in animal models
Animal work supports effects on BDNF expression and neuroprotection in ischaemia models.
What the evidence does not show
- The clinical evidence is almost entirely Russian-language and has not been replicated to Western regulatory standards.
- No major regulator outside Russia has assessed it.
- Claims about cognitive enhancement in healthy people are not what the studies examined.
Reported risks and adverse effects
- Reported as well tolerated in the studies that exist, which are of limited methodological quality.
- No long-term safety data meeting Western standards.
Regulatory status
A registered medicine in Russia. Not approved in the UK, EU or US.